CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Avedro, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Avedro, Inc.
201 Jones Road
Phone: (781) 768-3400p:781 768-3400 Waltham, MA  02451-1600  United States Fax: (302) 655-5049f:302 655-5049
This company was Merged or Acquired on 11/21/2019.
This company ceased filing statements with the SEC on 12/2/2019.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Avedro, Inc. is a commercial-stage ophthalmic medical technology company. The Company is focused on treating corneal ectatic disorders. Its Avedro Corneal Remodeling Platform is designed to stabilize and reshape the cornea utilizing corneal cross-linking in minimally invasive and non-invasive outpatient procedures to treat corneal ectatic disorders and correct refractive conditions. Its platform consists of KXL and Mosaic systems, which delivers ultraviolet A, light and a suite of single-use riboflavin drug formulations. Its KXL system is marketed to perform other corneal cross-linking procedures, such as Lasik Xtra. It offers Mosaic System for Photorefractive Intrastromal Cross-Linking (PiXL), Lasik Xtra and Accelerated Cross-Linking; KXL System for Lasik Xtra and Accelerated Cross-Linking, and Riboflavin Family for customizing each cross-linking procedures. The Company sells its products to ophthalmologists, hospitals and ambulatory surgery centers.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/201912/31/2018YesYes-YesYes

Industries
SIC Code Description
2834 Pharmaceutical preparations
3841 Surgical and medical instruments and apparatus

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
President, Chief Executive Officer, Director RezaZadno
Chief Financial Officer TomGriffin
Vice President - Engineering DesmondAdler
Chief Medical Officer Rajesh K.Rajpal
Chief Business Officer JamesSchuermann 1/1/2018 1/1/2018

Business Names
Business Name
AVDR
IROC Innocross AG

General Information
Number of Employees: 122 (As of 12/31/2018)
Outstanding Shares: 17,520,793 (As of 10/31/2019)
Shareholders: 123
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023